Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review

Jingping Yuan; Liang He; Bing Han; Yan Li
April 2017
World Journal of Surgical Oncology;4/11/2017, Vol. 15, p1
Academic Journal
Case Study
Background: Primary peritoneal papillary serous carcinoma (PPPSC) is an uncommon disease which has a high malignancy and a poor prognosis. Case presentation: We report here a long-term survival case of PPPSC with postoperative lung metastasis. A 62-year-old female patient with PPPSC was administered two cycles of neoadjuvant chemotherapy (NAC) followed by cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and six cycles of platinum-based (docetaxel + carboplatin) intraperitoneal chemotherapy postoperatively. The patient reached a complete remission at the completion of primary treatment. Malignant thoracic effusion and lung metastasis developed 5 months after the treatment. The patient underwent video-assisted thoracoscopic surgery plus hyperthermic intrapleural chemotherapy. Conclusions: Up to present, the patient has been survived with tumor for over 86 months with a good performance status, with only encapsulated effusion found at the latest follow-up. As a relatively new regime, the application of CRS + HIPEC in our patient has been proved example for MPE management, although more large-scale studies are needed to substantiate its efficiency and safety.


Related Articles

  • Lung cancer in Victoria: are we making progress? Mitchell, Paul L. R.; Thursfield, Vicky J.; Ball, David L.; Richardson, Gary E.; Irving, Louis B.; Torn-Broers, Yvonne; Giles, Graham G.; Wright, Gavin M. // Medical Journal of Australia;11/18/2013, Vol. 199 Issue 10, p674 

    The article presents a study to identify areas for improving management of patient with lung cancer which remains the greatest cause of death in Australia. It reviews a retrospective survey of all cases of lung cancer reported to the Victorian Cancer Registry from January 1 to June 30, 2003 and...

  • Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol. Kreuter, Michael; Vansteenkiste, Johan; Griesinger, Frank; Hoffmann, Hans; Dienemann, Hendrik; De Leyn, Paul; Thomas, Michael // BMC Cancer;2007, Vol. 7, p77 

    Background: Adjuvant chemotherapy has been proven to be beneficial for patients with early stage non-small cell lung cancer. However, toxicity and insufficient dose delivery have been critical issues with the chemotherapy used. Doublet regimens with pemetrexed, a multi-target folate inhibitor,...

  • Adjuvant breast cancer chemotherapy during late-trimester pregnancy: not quite a standard of care. Epstein, Richard J. // BMC Cancer;2007, Vol. 7, p92 

    Background: Diagnosis of breast cancer during pregnancy was formerly considered an indication for abortion. The pendulum has since swung to the other extreme, with most reviews now rejecting termination while endorsing immediate anthracycline-based therapy for any pregnant patient beyond the...

  • Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. Gruenberger, Birgit; Scheithauer, Werner; Punzengruber, Robert; Zielinski, Christoph; Tamandl, Dietmar; Gruenberger, Thomas // BMC Cancer;2008, Vol. 8, Special section p1 

    Background: Surgical resection of liver metastases arising from colorectal cancer is considered the only curative treatment option. However, many patients subsequently experience disease recurrence. We prospectively investigated whether neoadjuvant chemotherapy reduces the risk of recurrence...

  • Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04. Rayson, Daniel; Saint-Jacques, Nathalie; Younis, Tallal; Meadows, Jason; Dewar, Ron // CMAJ: Canadian Medical Association Journal;1/30/2007, Vol. 176 Issue 3, p327 

    Background: Waiting times for cancer care continue to be an important issue for Canadians. We evaluated 2 cohorts of breast cancer patients to compare changes in elapsed times to care, to determine the proportion of patients who received their postoperative oncology consultation within the...

  • Adjuvant Therapy for Women Over Age 65 With Breast Cancer. Sautter-Bihl, Marie-Luise; Souchon, Rainer; Gerber, Bernd // Deutsches Aerzteblatt International;5/27/2011, Vol. 108 Issue 21, following p371 

    A bibliography on the subject of adjuvant therapy for women over age 65 with breast cancer is presented which includes the articles "Treatment of breast cancer in older women," by Bernardi D. and colleagues, "Acute toxicity of curative radiotherapy in elderly patients," by Huguenin P. and...

  • Neo Adjuvant Chemotherapy in Locally Advanced Gastric Cancers of The Medical Oncology Department of The Hospital University of Blida (Algeria). Melzi, M. A.; Idir, H.; Bouzidi, W.; Bounedjar, A. // Pan Arab Journal of Oncology;Jun2016, Vol. 9 Issue 2, p35 

    Introduction: Gastric cancer is commonly diagnosed at locally advanced stage, with unresectable tumors. The use of neo adjuvant chemotherapy may lead to tumor down staging with possibilities of a surgical resection. We will evaluate in this study the efficacy and the safety of the neo adjuvant...

  • OP66 Tumor Profiling Tests In Early Breast Cancer: A Systematic Review. Harnan, Susan; Cooper, Katy; Stevens, John; Wong, Ruth; Tappenden, Paul; Bessey, Alice; Ward, Sue; Rafia, Rachid; Stein, Rob; Brown, Janet // International Journal of Technology Assessment in Health Care;2018 Supplement, Vol. 34, p24 

    Introduction: Tumor profiling tests can help to identify whether women with breast cancer need chemotherapy due to their risk of relapse, and some may be able to predict benefit from chemotherapy. We focused on four genetic tests: Oncotype DX (O-DX), MammaPrint (MMP), EndoPredict and Prosigna,...

  • The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. Sarfati, Diana; Hill, Sarah; Blakely, Tony; Robson, Bridget; Purdie, Gordon; Dennett, Elizabeth; Cormack, Donna; Dew, Kevin // BMC Cancer;2009, Vol. 9, Special section p1 

    Background: Comorbidity has a well documented detrimental effect on cancer survival. However it is difficult to disentangle the direct effects of comorbidity on survival from indirect effects via the influence of comorbidity on treatment choice. This study aimed to assess the impact of...

  • Polydatin, a natural precursor of resveratrol, induces cell cycle arrest and differentiation of human colorectal Caco2 cell. De Maria, Salvatore; Scognamiglio, Ilaria; Lombardi, Angela; Amodio, Nicola; Caraglia, Michele; Cartenì, Maria; Ravagnan, Gianpietro; Stiuso, Paola // Journal of Translational Medicine;2013, Vol. 11 Issue 1, p1 

    Background Human colon adenocarcinoma cells are resistant to chemotherapeutic agents, such as anthracyclines, that induce death by increasing the reactive oxygen species. A number of studies have been focused on chemo-preventive use of resveratrol as antioxidant against cardiovascular diseases,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics